The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients
-
Published:2020-06
Issue:6
Volume:38
Page:602.e1-602.e10
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Ogihara Koichiro, Kikuchi EijiORCID, Shigeta Keisuke, Okabe Takashi, Hattori Seiya, Yamashita Ryo, Yoshimine Shunsuke, Shirotake Suguru, Nakazawa Ryuto, Matsumoto KazuhiroORCID, Mizuno Ryuichi, Hara Satoshi, Oyama Masafumi, Masuda TakeshiORCID, Niwakawa Masashi, Oya Mototsugu
Reference27 articles.
1. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium;Sternberg;J Urol,1988 2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000 3. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study;Plimack;Lancet Oncol,2017 4. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study;Balar;Lancet Oncol,2017 5. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|